May 8, 2025
| Today’s news and insights for biopharma leaders
CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might push for higher standards in the review of medicines under his division's purview.
|
A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical acute pain. Viatris now plans to file for approval this year.
|
The startup’s first prospect is a heart medicine that works differently than the hypertrophic cardiomyopathy drugs developed by Bristol Myers and Cytokinetics.
|
Progress in gene editing, messenger RNA and cell therapies promise new kinds of medicines in the future. Explore the latest developments in the biotech landscape in
|
The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and operational investments in U.S. drug manufacturing.
|
UPDATED
A budget outline released by the administration shows it aims to lower HHS spending by about 26% next year, with deep cuts at the NIH and CDC.
|
|
Stronger connections lead to better outcomes. In this infographic, learn how to use key moments in the product lifecycle, from drug discovery to commercialization, to help transform patient care.
|
|
From Our Library
Trendline
Supported by Phil Inc
|
Trendline
Supported by EVERSANA
|
Trendline
Supported by Catalent
|
Infographic
Custom content for WCG
|
| 
